Challenges in the care of familial hypercholesterolemia: A community care perspective

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 10, 2015, Pages 1091-1100

  Brett, Tom ^a   Watts, Gerald F ^b,c   Arnold Reed, Diane E ^a   Bell, Damon A ^b,c,d,e   Garton Smith, Jacquie ^c,f   Vickery, Alistair W ^g   Ryan, Jacqueline D M ^b   Pang, Jing ^b  

^a UNIVERSITY OF NOTRE DAME   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e ST JOHN OF GOD HOSPITAL   (Australia)

^f Department of Heath Western Australia ^*  (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cardiovascular disease; cascade testing; Dutch Lipid Clinic Network Criteria; familial hypercholesterolaemia; index case; phenotypic testing; prevalence; primary tertiary care management; statins

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENCE; ADULTHOOD; CARDIOVASCULAR RISK; CHILDHOOD; CLINICAL FEATURE; COMMUNITY CARE; DRUG TARGETING; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HEALTH; GENETIC SCREENING; HUMAN; PATIENT CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PREGNANCY; PRIMARY MEDICAL CARE; PUBLIC HEALTH PROBLEM; REVIEW; RURAL POPULATION; BLOOD; HYPERLIPOPROTEINEMIA TYPE II;

CHOLESTEROL, LDL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II;

EID: 84942826788     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1082907     Document Type: Review

References (51)

1. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160(5):407-20
2. Austin MA, Hutter CM, Zimmern RL, et al. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004;160(5):421-9
3. Marks D, Thorogood M, Neil HA, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168(1):1-14
4. National Institute for Health and Clinical Excellence and The National Collaborating Centre for Primary Care. NICE Clinical Guideline 71: Identification and management of familial hypercholesterolaemia. National Collaborating Centre for Primary Care : Royal College of General Practitioners; London: 2008
5. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015. [Epub ahead of print]
6. Ademi Z, Watts GF, Amanda J, et al. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 2013;167(6):2391-6
7. Nherera L, Calvert NW, DeMott K, et al. Cost-effectiveness analysis of the use of high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010;26(3):529-36
8. Qureshi N, Humphries S, Seed M, et al. Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract 2009;59:773-8
9. Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97(11):3956-64
10. Lansberg PJ, Tuzgöl S, van de Ree MA, et al. [Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands]. Ned Tijdschr Geneeskd 2000;144(30):1437-40
11. Watts GF, Shaw JE, Pang J, et al. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol 2015;185:69-71
12. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010;77(6):572-80
13. Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012;76(5):387-401
14. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34(45):3478-90a
15. Bell DA, Garton-Smith J, Vickery A, et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ 2014;23(4):309-13
16. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011;12(2):221-63
17. Hamilton-Craig IR. Prescribing statins: the real issues. Med J Aust 2014;200(8):440-1
18. Schaffer AL, Buckley NA, Dobbins TA, et al. The crux of the matter: Did the ABC's Catalyst program change statin use in Australia? Med J Aust 2015;202(11):591-4
19. Humphries S, Hadfield G. Identifying patients with familial hypercholesterolaemia in primary care (Editorial). Heart 2008;94:695-6
20. Slack J. Risks of ischaemic heart disease in familial hypercholesterolaemic states. Lancet 1969;2:1380-2
21. Australian Bureau of Statistics, Cat 4839.0 - Patient Experiences in Australia: Summary of Findings, 2013-2014. 2014;Australian Bureau of Statistics: Canberra
22. Bell DA, Hooper AJ, Bender R, et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann Clin Biochem 2012;49(6):534-7
23. Bell DA, Bender R, Hooper AJ, et al. Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clin Chim Acta 2013;422:21-5
24. Bell DA, Hooper AJ, Edwards G, et al. Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis 2014;234(2):469-72
25. Kirke A, Watts G, Emery J. Detecting familial hypercholesterolaemia in general practice. Aust Fam Physician 2012;41:965-8
26. Britt H, Miller GC, Charles J, et al. General practice in Australia, health priorities and policies 1998 to 2008. In: Britt H, Miller GC, editors. General Practice series. AIHW; Canberra, Australia: 2009
27. Royal australian college of general practice. Philosophy and foundation of general practice. 2011. Available from: http://curriculum.racgp.org.au/statements/philosophy-and-foundation-of-general-practice/[Last accessed 17 June 2015]
28. Arnold-Reed DE, Brett T, Troeung L, et al. Multimorbidity in patients enrolled in a community based methadone program delivered through general practice. J Co-morbidity 2014;4(1):46-54
29. Brett T, Arnold-Reed DE, Popescu A, et al. Multimorbidity in Patients Attending 2 Australian Primary Care Practices. Ann Fam Med 2013;11(6):535-42
30. Brett T, Arnold-Reed DE, Troeung L, et al. Multimorbidity in a marginalised, street-health Australian population: a retrospective cohort study. BMJ Open 2014;4:8
31. Rich EC, Burke W, Heaton CJ, et al. Reconsidering the Family History in Primary Care. J Gen Intern Med 2004;19(3):273-80
32. Acheson LS, Wiesner GL, Zyzanski SJ, et al. Family history-taking in community family practice: implications for genetic screening. Genet Med 2000;2(3):180-5
33. Kirke AB, Barbour RA, Burrows S, et al. Systematic detection of familial hypercholesterolaemia in primary health care: a community based prospective study of three methods. Heart Lung Circ 2015;24(3):250-6
34. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303-8
35. Watts GF, Juniper A, van Bockxmeer F, et al. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. Int J Evid Based Healthc 2012;10(3):211-21
36. Brett T, Arnold-Reed D, Phan C, et al. The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute cardiovascular risk reduction. Br J Gen Pract 2012;62(594):e22-8
37. Vickery AW, Bell D, Garton-Smith J, et al. Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services. Heart, Lung and Circulation 2014;23(12):1158-64
38. Weiner K, Durrington PN. Patients' understandings and experiences of familial hypercholesterolemia. Community Genet 2008;11(5):273-82
39. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014;171(3):309-25
40. Pedersen KM, Humphries SE, Roughton M, et al. National Clinical Audit of the Management of Famililial Hypercholesterolaemia 2010. Clinical Standards Department. Royal College Physicians; London: 2010
41. Weng SF, Kai J, Andrew Neil H, et al. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 2015;238(2):336-43
42. Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 2014;8(4):390-400
43. Bell DA, Watts GF. Response to familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin Cardiol 2014;37(6):386-7
44. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008;46(6):791-803
45. Bell DA, Kirke AB, Barbour R, et al. Can patients be accurately assessed for familial hypercholesterolaemia in primary care? Heart Lung Circ 2014;23(12):1153-7
46. Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008;11(1):26-35
47. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97(14):1175-81
48. Page MM, Stefanutti C, Sniderman A, et al. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Clin Sci (Lond) 2015;129(1):63-79
49. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209(1):189-94
50. Amundsen AL, Khoury J, Iversen PO, et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 2006;189(2):451-7
51. Toleikyte I, Retterstol K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation 2011;124(15):1606-14